World of DTC Marketing

APRIL 11, 2021

Both Pfizer and Moderna stand to make billions, and even though J&J said they would not make money on the first batch, they are already positioning yearly Covid Vaccine shots that could net them billions in sales. Antibody tests indicate you had a previous infection and that you may have some level of protection against the virus.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3

Antibody 52

Antibody Trials Production Clinical Trials 52

pharmaphorum

FEBRUARY 10, 2022

In its annual results statement, AZ said that it took the decision on the back of data showing that a third dose of Vaxzevria increased the immune response to new variants, including Omicron which is currently driving new COVID-19 cases around the world. ” Vaxzevria added almost $4 billion to its revenues last year, including $1.8

Vaccination 52

Vaccination Vaccine Development Immune Response 52

pharmaphorum

MARCH 28, 2022

GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus. The antibody made a substantial contribution to GSK’s top-line last year, adding around $1.25 2 subvariant of Omicron.

Antibody 52

Antibody Immune Response Regulation Sales 52

XTalks

MAY 2, 2024

The firm predicts sales of KarXT could reach $2.8 Current drugs on the market for schizophrenia include Lundbeck and Otsuka’s Rexulti (brexpiprazole) and Eli Lilly’s Prozac (fluoxetine), but these drugs derive the majority of their sales from other conditions, including severe forms of depression or Alzheimer’s agitation. billion ($1.5

Drugs 52

Drugs FDA Approval Sales Vaccination 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

DECEMBER 21, 2020

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2 Other recent deals include a $2.8 Other recent deals include a $2.8

Immune Response 59

Immune Response Sales Antibody Pharma Companies 59

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccination 133

Vaccination Vaccine Clinical Trials Clinical Trials 133

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 67

Drugs Immune Response Allergies Sales 67

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 98

Doctors Doctor Manufacturing Drugs 98

The Pharma Data

JANUARY 22, 2021

An Ohio State University review of 49 vaccine studies dating back 30 years examined how stress, depression and healthy behaviors, such as exercise, can affect immune response to a vaccine. “What we see is that stress can delay your antibody response to the vaccine,” Kiecolt-Glaser said.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

JANUARY 4, 2023

They both also include tiered royalties on sales of any products emerging from the partnerships. The hypothesis is that it will induce immune tolerance by stimulating anti-inflammatory regulatory T- (Treg) cells and cytokines that dampen down the immune response.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

The Pharma Data

JUNE 30, 2021

Yasmin Parr’s study of FeLV shows that the outcome of FeLV infection is influenced by the host immune response, with progressively infected cats, so cats whose conditions are worsening, having weaker immune responses. “In billion euros in 2020 and presence in more than 150 countries.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

NOVEMBER 17, 2020

t for the treatment of autoimmune diseases , which occur when the body’s immune system attacks its own cells and tissues as foreign invaders. . While the antibody responsible for immune-mediated diseases is yet to be identified, they are thought to be regulated by an aberrant immune response. Source link.

Immune Response 52

Immune Response Licensing Licensing Sales 52

pharmaphorum

FEBRUARY 14, 2022

billion in sales last year, slightly down as a result of the pandemic. Like Shingrix, CRV-101 is a subunit vaccine based on the glycoprotein E (gE) antigen of the herpes zoster virus, delivered alongside an adjuvant to boost the immune response.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

The Pharma Data

JANUARY 12, 2021

The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells. It is being developed for the treatment of solid tumors.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Development 52

pharmaphorum

AUGUST 16, 2020

The fund has already been deployed to order Gilead’s antiviral drug Veklury (remdesivir) and apheresis equipment to collect antibodies from the blood of patients who have recovered from COVID-19.

Vaccination 109

Vaccination Vaccine Immune Response Trials 109

XTalks

JULY 8, 2021

The drugs are monoclonal antibodies against the IL-6 receptor. Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed.

Doctors 52

Doctors Doctor Manufacturing Drugs 52

XTalks

MARCH 8, 2024

According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1 Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK.

Drugs 59

Drugs FDA Approval Production Immune Response 59

XTalks

MAY 1, 2023

At its peak sales, Qalsody is expected to generate around $300 million for Biogen. Tegoprubart is an anti-CD40L antibody designed to inhibit the CD40 and CD11 costimulatory signaling pathways. Developed by Eisai and Biogen, Leqembi is an amyloid beta-directed antibody.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

Delveinsight

AUGUST 26, 2021

Under the agreement, Shape is eligible to receive an initial payment and payments for hitting development, regulatory and sales milestones potentially exceeding USD 3 billion in aggregate value. Researchers will compare the two-time points to recognize the optimum timing of peak immune response following nasal vaccination.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on. That was down from almost $2.6

Antibody 104

Antibody Vaccination Vaccine Immune Response 104

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

JANUARY 19, 2021

Other products include CLNB-049, a bispecific antibody against FLT3 and CD3 and CLN-619, a monoclonal antibody that simulates NK and T-cell responses. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor. This is planned to raise about $25 million.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Debiopharm is interested in innovative therapeutic platforms for tomorrow,” Gibbs says. “We

Genome 104

Genome Genomics Medicine Development 104

The Pharma Data

MARCH 8, 2021

Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to human interleukin-1beta (IL-1?) Pro-tumor inflammation enables tumor development by driving cancer-causing processes and by suppressing anti-tumor immune responses 9,10. 6 , 7 and neutralizes IL-1? By neutralizing IL-1?,

Trials 52

Trials Immune Response Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. government allocation program. Regeneron Pharmaceuticals, Inc.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

NOVEMBER 15, 2023

Valneva recently reported that it has been experiencing an increase in sales of its other vaccines due to the “recovery of the travel industry.” It appears the company has already done so as its quarterly earnings report included $96 million and $117 million of additional revenue from the sale of the PRV in its 2023 revenue guidance.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

pharmaphorum

JULY 14, 2021

The bulk of Prevnar 13 sales come from use in adults, and with Merck & Co in the final stages of regulatory review of its rival vaccine V114 – covering 15 serotypes and filed for adult use – the franchise is facing some serious competition for the first time. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

The Pharma Data

FEBRUARY 8, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

FEBRUARY 4, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccination Vaccine Production 52

pharmaphorum

SEPTEMBER 20, 2022

Though there is little question that sales generated in the area will come back to earth in the years to come, the industry’s outlook on the potential of vaccines and the infectious diseases area has been permanently shifted. This all comes down to the impact of the pandemic. Boosting vaccine equity.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98